Resolve Therapeutics lands $5.8M to crack the code on Lupus

Resolve Therapeutics, a 2-year-old Seattle biotechnology spin off from the University of Washington, has raised $5.8 million in new financing from  New Science Ventures, WRF Capital and Easton Capital. The company will use the funds to continue to develop therapeutics for the treatment of Lupus, a life-threatening autoimmune disease that affects 1.5 million people in the United… Read More